Overview

Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, randomized (1:1 randomization ratio) study of either exemestane or exemestane plus celecoxib in postmenopausal women with ABC having progressed on tamoxifen.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Celecoxib
Exemestane
Tamoxifen